866-897-8297

Call Is Confidential & Toll Free

Brilinta

Brilinta (trade name Brilinta in the US, Brilique and Possia in the EU) is a platelet aggregation inhibitor produced by AstraZeneca. Unlike clopidogrel, brilinta is not a prodrug and does not require metabolic activation. The drug was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011.

Plasma concentrations of brilinta are slightly increased (12–23%) in elderly patients, women, patients of Asian ethnicity, and patients with mild hepatic impairment. They are decreased in patients that described themselves as ‘coloured’ and such with severe renal impairment. These differences are considered clinically irrelevant. In Japanese people, concentrations are 40% higher than in Caucasians, or 20% after body weight correction. The drug has not been tested in patients with severe hepatic impairment.

Bleeding is the expected pharmacologic effect of overdosing. If bleeding occurs, appropriate supportive measures should be taken. Other effects of overdose may include gastrointestinal effects (nausea, vomiting, diarrhea) or ventricular pauses.

Imprints


Drug: Brilinta
Strength: 90 Mg
Pill Imprint: 90 T
Color: Yellow
Shape: Round

View Images & Details

Drug: Brilinta
Strength: 60 Mg
Pill Imprint: 60 T
Color: Pink
Shape: Round

View Images & Details
Disclaimer: We strive to ensure that the content on pilladdictions.com is current and factual at the time it was written. However, because new information and discoveries are always becoming available, we are not making any representations or warranties with respect to this content. Please always rely on the guidance of your physician for information about the drugs you are taking and the impacts they may or may not have on your health.

Questions About Prescription Drug Addiction?

(888) 740-2069

Questions About Prescription Drug Addiction?